The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden

BACKGROUND: Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK)/c-ros oncogene 1 (ROS1) tyrosine kinase inhibitor (TKI) with efficacy in patients with ALK-rearranged non-small-cell lung cancer (NSCLC) previously treated with a second-generation ALK inhibitor or with first- and second-g...

Descripción completa

Detalles Bibliográficos
Autores principales: Nilsson, Fredrik O. L., Asanin, Sandra T., Masters, Elizabeth T., Iadeluca, Laura, Almond, Chrissy, Cooper, Miranda, Smith, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298221/
https://www.ncbi.nlm.nih.gov/pubmed/34080140
http://dx.doi.org/10.1007/s40273-021-01015-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298221/
https://www.ncbi.nlm.nih.gov/pubmed/34080140
http://dx.doi.org/10.1007/s40273-021-01015-8

Ejemplares similares